Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hur,Jin-Wuk | - |
dc.contributor.author | Choi,Chan-Bum | - |
dc.contributor.author | Bae,Sang-Cheol | - |
dc.date.accessioned | 2022-12-21T10:43:39Z | - |
dc.date.available | 2022-12-21T10:43:39Z | - |
dc.date.created | 2022-09-16 | - |
dc.date.issued | 2006-08 | - |
dc.identifier.issn | 0219-0494 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/181136 | - |
dc.description.abstract | Tumor necrosis factor (TNF) blockers have become an important treatment in rheumatoid arthritis (RA) with its proven effectiveness. But it is not universally effective in all patients and it comes with a relatively high economic burden. We should use them effectively. Advances in pharmacoeconomics and pharmacogenetics may be able to help us reach this goal. This article will review our clinical experience of biological agents to treat RA at Hanyang University in Korea, with emphasis on the current therapies targeting TNF and the rational use of theses agents in RA. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.title | Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi,Chan-Bum | - |
dc.contributor.affiliatedAuthor | Bae,Sang-Cheol | - |
dc.identifier.doi | 10.1111/j.1479-8077.2006.00189.x | - |
dc.identifier.scopusid | 2-s2.0-33745956774 | - |
dc.identifier.bibliographicCitation | APLAR Journal of Rheumatology, v.9, no.2, pp.146 - 149 | - |
dc.relation.isPartOf | APLAR Journal of Rheumatology | - |
dc.citation.title | APLAR Journal of Rheumatology | - |
dc.citation.volume | 9 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 146 | - |
dc.citation.endPage | 149 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | abatacept | - |
dc.subject.keywordPlus | adalimumab | - |
dc.subject.keywordPlus | antihistaminic agent | - |
dc.subject.keywordPlus | C reactive protein | - |
dc.subject.keywordPlus | cyclosporin | - |
dc.subject.keywordPlus | disease modifying antirheumatic drug | - |
dc.subject.keywordPlus | etanercept | - |
dc.subject.keywordPlus | golimumab | - |
dc.subject.keywordPlus | hydroxychloroquine | - |
dc.subject.keywordPlus | infliximab | - |
dc.subject.keywordPlus | leflunomide | - |
dc.subject.keywordPlus | methotrexate | - |
dc.subject.keywordPlus | monoclonal antibody | - |
dc.subject.keywordPlus | nonsteroid antiinflammatory agent | - |
dc.subject.keywordPlus | placebo | - |
dc.subject.keywordPlus | rituximab | - |
dc.subject.keywordPlus | salazosulfapyridine | - |
dc.subject.keywordPlus | steroid | - |
dc.subject.keywordPlus | tumor necrosis factor alpha | - |
dc.subject.keywordPlus | tumor necrosis factor derivative | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | cost effectiveness analysis | - |
dc.subject.keywordPlus | drug dose regimen | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug eruption | - |
dc.subject.keywordPlus | dyspnea | - |
dc.subject.keywordPlus | economic aspect | - |
dc.subject.keywordPlus | erythema | - |
dc.subject.keywordPlus | erythrocyte sedimentation rate | - |
dc.subject.keywordPlus | face edema | - |
dc.subject.keywordPlus | headache | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | hypertension | - |
dc.subject.keywordPlus | hypotension | - |
dc.subject.keywordPlus | injection site reaction | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | lupus like syndrome | - |
dc.subject.keywordPlus | nausea | - |
dc.subject.keywordPlus | pharmacogenetics | - |
dc.subject.keywordPlus | pneumonia | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | pruritus | - |
dc.subject.keywordPlus | rheumatoid arthritis | - |
dc.subject.keywordPlus | single nucleotide polymorphism | - |
dc.subject.keywordPlus | thorax pain | - |
dc.subject.keywordPlus | tuberculosis | - |
dc.subject.keywordPlus | upper respiratory tract infection | - |
dc.subject.keywordPlus | vomiting | - |
dc.subject.keywordAuthor | Etanercept | - |
dc.subject.keywordAuthor | Infliximab | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | TNF-�� | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/j.1479-8077.2006.00189.x | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.